TABLE III. Summary of Clinical Features Among BRCA2mut Men, Study Control Subjects (“Non-Carrier Controls”), and the General Population (“SEER Population”).
| BRCA2mut cases, n (%) |
Non-carriers controls, n (%) |
P-value | SEER population, n (%) |
P-value | |
|---|---|---|---|---|---|
| n | 261 | 7,109 | 494,739 | ||
| Median age in years (mean) | 61.6 (61.7) | 65 (62.2) | 0.12 | 66 (66.5) | <0.001a |
| PSA | 0.95 | ||||
| ≤3ng/dl | 4 (5) | 10 (10) | – | ||
| >3ng/dl | 76 (95) | 89 (90) | – | ||
| Unknown | 181 | 7,010 | – | ||
| Median PSA ng/dl (mean) | 15.1 (19.5) | 11 (11.1) | <0.001b | – | |
| Gleason’s score | <0.001b | ||||
| <7 | 65 (29) | 1,972 (46) | – | ||
| ≥7 | 157 (71) | 2,366 (54) | – | ||
| Unknown | 39 | 2,771 | – | ||
| Stage overall | 0.006b | <0.001a | |||
| ≤T2 | 100 (53) | 1,385 (65) | 429,531 (90) | ||
| T3/T4 | 88 (47) | 750 (35) | 45,936 (10) | ||
| Unknown | 73 | 4974 | 19,272 | ||
| Localized | <0.001b | <0.001a | |||
| M0 | 139 (74) | 2,322 (92) | 452,296 (96) | ||
| M1 | 48 (26) | 191 (8) | 18,341 (4) |
a
Statistically significant difference between BRCA2mut and SEER control subjects.
b
Statistically significant difference between BRCA2mut and non-carrier control subjects.